Evidence map›Paper›PMID 40664994›Full record

ArticleScientific reports2025

The inner nuclear membrane protein, Banf1, has an essential role in triple negative breast cancer cell proliferation and survival.

Maddison Rose, Joshua T Burgess, Chee Man Cheong, Iain Richard, Amila Suraweera, Mark N Adams, Pascal H G Duijf, Kenneth J O'Byrne, Derek J Richard, Emma Bolderson

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Maddison RoseCancer Genomics Program, Centre for Genomics and Personalised Health, School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Kelvin Grove, Brisbane, Australia.
Joshua T BurgessCancer Genomics Program, Centre for Genomics and Personalised Health, School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Kelvin Grove, Brisbane, Australia.
Chee Man CheongCancer Genomics Program, Centre for Genomics and Personalised Health, School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Kelvin Grove, Brisbane, Australia.
Iain RichardCancer Genomics Program, Centre for Genomics and Personalised Health, School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Kelvin Grove, Brisbane, Australia.
Amila SuraweeraCancer Genomics Program, Centre for Genomics and Personalised Health, School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Kelvin Grove, Brisbane, Australia.
Mark N AdamsCancer Genomics Program, Centre for Genomics and Personalised Health, School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Kelvin Grove, Brisbane, Australia.
Pascal H G DuijfCentre for Cancer Biology, University of South Australia & SA Pathology, Adelaide, SA, Australia.
Kenneth J O'ByrneCancer Genomics Program, Centre for Genomics and Personalised Health, School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Kelvin Grove, Brisbane, Australia.
Derek J RichardCancer Genomics Program, Centre for Genomics and Personalised Health, School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Kelvin Grove, Brisbane, Australia.
Emma BoldersonCancer Genomics Program, Centre for Genomics and Personalised Health, School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Kelvin Grove, Brisbane, Australia. emma.bolderson@qut.edu.au.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Triple negative breast cancers (TNBCs) are a heterogenous subcategory of breast cancers which have significantly worse survival outcomes compared to other breast cancer subtypes. However, limited advances have been made towards a targeted TNBC therapeutic and traditional chemotherapies remain the frontline therapy. Therefore, this study aimed to examine the therapeutic potential of a novel TNBC target, Barrier-to-Autointegration Factor 1 (Banf1), including determining Banf1 expression and cellular localisation in non-malignant breast cells and a panel of TNBC cell lines. Bioinformatic analysis of patient samples demonstrated that Banf1 is overexpressed in all breast cancer stages and subtypes. Banf1 depletion inhibited proliferation and induced mitotic arrest in TNBC cells via loss of nuclear envelope integrity and aberrant nuclear morphology, inducing TNBC tumour cell-specific cell death. These findings highlight the significant overexpression and functional involvement of Banf1 in TNBC progression and suggests that it may have potential as a novel anti-cancer target, supporting further investigation.

Indexed as

DNA-Binding ProteinsNuclear ProteinsTriple Negative Breast NeoplasmsCell Line, TumorCell ProliferationCell SurvivalFemaleGene Expression Regulation, NeoplasticHumansNuclear EnvelopeDNA-Binding ProteinsNuclear ProteinsBanf1Breast cancerMitosisNuclear envelope

Identifiers

PMID40664994
PMCPMC12264273

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.